Renal Hypoplasia Management

Follow-up and Monitoring

• Patients with renal hypoplasia should have follow-up every 12-24 months with renal ultrasound, and clinical visits every 6-12 months for adults or every 3-6 months for infants and young children, as recommended by the Kidney International guidelines 1
• Renal ultrasound should be performed every 12-24 months to monitor for nephrocalcinosis, kidney stones, and signs of secondary obstructive uropathy in patients with renal hypoplasia, as recommended by the Kidney International guidelines 1

Clinical Evaluation

• Clinical visits for patients with renal hypoplasia should focus on signs of dehydration, degree of polyuria, muscular weakness, growth and psychomotor development (in children), and fatigue and palpitations (in adults), according to the Kidney International guidelines 1
• Patients with renal hypoplasia should undergo evaluation of acid-base status, serum electrolytes, renal function tests, parathyroid hormone (PTH), urinary calcium excretion, microalbuminuria (in adults), and urine osmolality to test for secondary nephrogenic diabetes insipidus, as recommended by the Kidney International guidelines 1

Specialized Care

• Patients with renal hypoplasia should ideally be followed in specialized centers with experience in renal tubular disorders to facilitate optimal care, as suggested by the Kidney International guidelines 1
• Children with growth retardation despite optimized metabolic control should be considered for growth hormone deficiency evaluation, according to the Kidney International guidelines 1
• Patients with renal hypoplasia complaining of palpitations or syncope should undergo further cardiology work-up, as recommended by the Kidney International guidelines 1
• Quality of life should be evaluated using age-appropriate scales at regular intervals in patients with renal tubular disorders, as recommended by the Kidney International guidelines 1

Medication Management

• Sodium bicarbonate supplementation is recommended when serum bicarbonate is less than 18 mmol/L, with a target serum bicarbonate of at least 22 mmol/L, as recommended by the American College of Physicians and the American Journal of Kidney Diseases 2, 3, 4
• Bicarbonate therapy should be limited to severe metabolic acidosis (pH < 7.0-7.1), and sodium bicarbonate is the first-line medication for metabolic acidosis, with a dosage of 1-2 mEq/kg IV given slowly for acute situations, as recommended by Pediatrics and the American Journal of Kidney Diseases 5, 6, 3
• Potassium citrate dose should be adjusted based on urinary citrate levels and pH, and treatment should be discontinued if hyperkalemia, significant rise in serum creatinine, or significant fall in blood hematocrit/hemoglobin occurs, as recommended by Kidney International 1
• The following medications are not recommended for routine use in patients with renal tubular acidosis (RTA): K-sparing diuretics, ACE inhibitors, Angiotensin receptor blockers, and Thiazide diuretics, due to the risk of worsening salt wasting and life-threatening hypovolemia, as recommended by the Kidney International society 1
• The following table summarizes the medication management for renal hypoplasia:

Laboratory Monitoring

• Regular laboratory monitoring should include serum electrolytes, arterial or venous blood gases, and renal function tests, as suggested by the National Institute of Diabetes and Digestive and Kidney Diseases and the National Kidney Foundation 2, 1
• Avoid excessive alkali therapy which can lead to metabolic alkalosis, as warned by the American College of Medical Toxicology 2
• Bicarbonate therapy has not consistently reduced morbidity or mortality in lactic acidosis and ketoacidosis, and potential adverse effects include worsening intracellular acidosis and reduced ionized calcium, as noted by the Society of Critical Care Medicine and the American Journal of Kidney Diseases 3

Pregnancy and Special Considerations

• Alkali therapy should be continued during pregnancy with careful monitoring, and a joint management plan should be established with nephrology and obstetrics, as suggested by the Kidney International guidelines 1
• Infants with methemoglobinemia from diarrhea and acidosis may improve with aggressive hydration and bicarbonate correction alone if methemoglobin level is less than 20%, as recommended by the American Academy of Pediatrics 7
• Chronic kidney disease with persistent acidosis (bicarbonate < 18 mmol/L) should be treated with sodium bicarbonate, with a target serum bicarbonate ≥ 22 mmol/L, as recommended by the American Journal of Kidney Diseases 2, 4, 3